Upsher-Smith in research link with Lundbeck

Through its UK Proximagen subsidiary, US drugmaker Upsher-Smith Laboratories has entered into a preclinical development agreement with Denmark-based CNS drug specialist Lundbeck (LUND: CO) to further its research program related to protein kinase inhibitors.

This transaction is part of Upsher-Smith's long-term strategy to advance its current product portfolio of branded drugs. Specific terms related to the deal have not been disclosed.

Upsher-Smith has a particular focus on developing therapies to assist people suffering from central nervous system diseases, and also markets products relating to cardiology, dermatology and women's health.

"Upsher-Smith is pleased to announce today's development agreement with Lundbeck. We are very impressed with the world-class research conducted by Lundbeck and excited about the opportunity to bring a new therapy forward that may benefit patients," said Mark Evenstad, president and chief executive of Upsher-Smith.

"Forming successful alliances is a key strategic objective for Lundbeck. We share Upsher-Smith's commitment to develop therapies that may have the potential to improve the lives of people living with challenging medical conditions," added Ulf Wiinberg, CEO of Lundbeck.